Pre-Procedural Atorvastatin Mobilizes Endothelial Progenitor Cells: Clues to the Salutary Effects of Statins on Healing of Stented Human Arteries
2011

Atorvastatin and Endothelial Progenitor Cells in Heart Procedures

Sample size: 20 publication Evidence: moderate

Author Information

Author(s): Hibbert Benjamin, Ma Xiaoli, Pourdjabbar Ali, Simard Trevor, Rayner Katey, Sun Jiangfeng, Chen Yong-Xiang, Filion Lionel, O'Brien Edward R.

Primary Institution: University of Ottawa Heart Institute

Hypothesis

High dose Atorvastatin therapy initiated prior to PCI mobilizes EPCs that may be capable of enhancing arterial repair.

Conclusion

High dose Atorvastatin therapy pre-PCI improves EPC number and function in humans, which may explain the clinical benefits seen in patients undergoing coronary interventions.

Supporting Evidence

  • EPC levels increased 3.5-fold with Atorvastatin treatment before PCI.
  • CAC levels also rose significantly with Atorvastatin therapy.
  • The study included a control group receiving standard therapy for comparison.

Takeaway

This study found that giving patients a high dose of Atorvastatin before heart procedures helps their body produce more special cells that help heal blood vessels.

Methodology

Patients were randomized to receive either Atorvastatin or standard therapy before undergoing PCI, and EPCs were measured using flow cytometry.

Potential Biases

Recruitment of statin-naïve patients was challenging due to the common use of statins in the population.

Limitations

The study had a small sample size and was limited to male patients, which may affect the generalizability of the results.

Participant Demographics

All participants were male patients undergoing PCI, aged 59.5 to 63 years.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0016413

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication